Naltrexone modification of drinking effects in a subacute treatment and bar-lab paradigm: influence of OPRM1 and dopamine transporter (SLC6A3) genes.
- Authors
- Anton, Raymond F; Voronin, Konstantin K; Randall, Patrick K; Myrick, Hugh; Tiffany, Abraham
- Year
- 2012
- Journal
- Alcoholism, clinical and experimental research
- PMID
- 22551036
- DOI
- 10.1111/j.1530-0277.2012.01807.x
- PMCID
- PMC3414671
BACKGROUND: Naltrexone is moderately effective for the treatment of alcohol dependence, but there is great individual variability. The opioid receptor (OPRM1) single nucleotide polymorphism (SNP) asn40asp has been shown to alter alcohol and naltrexone response in animals and humans. In addition, the brain opioid and dopamine systems interact and might underlie drinking and craving. This study investigated the effects of the OPRM1 SNP and dopamine transporter (DAT) variable number of tandem repeat (VNTR) genetic differences on drinking, alcohol effects, and naltrexone response under controlled conditions in nontreatment-seeking alcoholics. METHODS: Two hundred and sixty-five nontreatment-seeking individuals with alcohol dependence were genotyped a priori for the OPRM1 asn40asp SNP and post hoc for DAT (SLC6A3) 9 and 10 VNTRs. Asp40 carriers (nΒ =Β 43) and matched asn40 homozygotes (nΒ =Β 40) were randomized to naltrexone or placebo for 7Β days before receiving a priming drink and limited-access alcohol consumption in a bar-lab setting. Effects of genotypes on natural drinking as well as drinking, alcohol effects, and response to naltrexone in the bar-lab setting were examined by genotype. RESULTS: There were no significant main effects of naltrexone or OPRM1 genotype, or any medication by OPRM1 interaction, on drinking variables. However, in individuals who had at least one DAT 9 VNTR, and who were also OPRM1 asn40 homozygotes, naltrexone reduced drinks/d consumed under natural conditions (pΒ =Β 0.006), but not in the bar-lab. OPRM1 asn40 homozygotes (pΒ =Β 0.028) and DAT 9 VNTR carriers (pΒ =Β 0.032) had more stimulation to alcohol after the priming drink. CONCLUSIONS: This study does not support a salient role for the OPRM1 asp40 alone in predicting drinking or naltrexone effects. However, although exploratory and in need of replication, it introduces the possibility that epistasis between the OPRM1 gene and DAT gene might need to be taken into account when examining differential genetic response to alcohol or medication treatment, especially in early-stage alcoholics.
Drinking (drinks/day) under natural conditions in non-treatment seeking alcoholics while taking naltrexone and placebo by OPRM1 and DAT genotypes. There was a significant three-way interaction of medication group by OPRM1 by DAT (see text for detail). Those with at least one DAT 9 VNTR and who were OPRM1 asn40 homozygotes had the greatest response to naltrexone. Sample size (n) for each group is given in insert boxes within each column.
Alcohol-induced stimulation after a priming drink based on OPRM1 and DAT genotypes. There were main effects of OPRM1 genotype (asn40 more than asp40) as well as DAT genotype (9 VNTR carriers more than 10 VNTR homozygotes). See text for detail.
No entities extracted from this document yet.
No uploaded files.
In this knowledge base
External
| Title | Authors | Journal | Year | Link |
|---|---|---|---|---|
| A review of the existing pharmacogenomic literature of naltrexone for use in alcohol use disorder. | Counts C et al. | β | 2025 | β |
| Neural cue reactivity and intrinsic functional connectivity in individuals with alcohol use disorder following treatment with topiramate or naltrexone. | Logge WB et al. | β | 2025 | β |
| Epigenetic moderators of naltrexone efficacy in reducing heavy drinking in Alcohol Use Disorder: a randomized trial. | Schacht JP et al. | β | 2022 | β |
| Randomized Controlled Trial of an Alcohol-related Sexual Risk Reduction Intervention with Adolescents: The Role of Neurocognitive Activation During Risky Decision-Making. | Bryan AD et al. | β | 2021 | β |
| Opioid and Dopamine Genes Interact to Predict Naltrexone Response in a Randomized Alcohol Use Disorder Clinical Trial. | Anton RF et al. | β | 2020 | β |
| Pharmacotherapies and personalized medicine for alcohol use disorder: a review. | Lohoff FW | β | 2020 | β |
| Systematic review and meta-analysis of the moderating effect of rs1799971 in OPRM1, the mu-opioid receptor gene, on response to naltrexone treatment of alcohol use disorder. | Hartwell EE et al. | β | 2020 | β |
| Naltrexone effects on subjective responses to alcohol in the human laboratory: A systematic review and meta-analysis. | Ray LA et al. | β | 2019 | β |
| Neuroimaging findings from an experimental pharmacology trial of naltrexone in heavy drinkers of East Asian descent. | Lim AC et al. | β | 2019 | β |
| Pharmacogenetics of alcohol addiction: current perspectives. | Zastrozhin MS et al. | β | 2019 | β |
| A Critical Review of Methods and Results in the Search for Genetic Contributors to Alcohol Sensitivity. | Schuckit MA | β | 2018 | β |
| Dopaminergic Genetic Variation Influences Aripiprazole Effects on Alcohol Self-Administration and the Neural Response to Alcohol Cues in a Randomized Trial. | Schacht JP et al. | β | 2018 | β |
| Pharmacogenetic Effects of Naltrexone in Individuals of East Asian Descent: Human Laboratory Findings from a Randomized Trial. | Ray LA et al. | β | 2018 | β |
| The OPRM1 A118G polymorphism: converging evidence against associations with alcohol sensitivity and consumption. | Sloan ME et al. | β | 2018 | β |
| A prospective study of genetic factors, human laboratory phenotypes, and heavy drinking in late adolescence. | Hendershot CS et al. | β | 2017 | β |
| Aripiprazole Suppression of Drinking in a Clinical Laboratory Paradigm: Influence of Impulsivity and Self-Control. | Anton RF et al. | β | 2017 | β |
| Effects of naltrexone on alcohol self-administration and craving: meta-analysis of human laboratory studies. | Hendershot CS et al. | β | 2017 | β |
| Efficacy of Naltrexone for the Treatment of Alcohol Dependence in Latino Populations. | LΓ³pez CM et al. | β | 2017 | β |
| Endogenous opioid system: a promising target for future smoking cessation medications. | Norman H et al. | β | 2017 | β |
| Independent and Interactive Effects of OPRM1 and DAT1 Polymorphisms on Alcohol Consumption and Subjective Responses in Social Drinkers. | Weerts EM et al. | β | 2017 | β |
| Network analysis of the genomic basis of the placebo effect. | Wang RS et al. | β | 2017 | β |
| Promising pharmacogenetic targets for treating alcohol use disorder: evidence from preclinical models. | Rinker JA et al. | β | 2017 | β |
| Alcohol-Induced Stimulation Mediates the Effect of a GABRA2 SNP on Alcohol Self-Administrated among Alcohol-Dependent Individuals. | Boyd SJ et al. | β | 2016 | β |
| Associations of OPRM1 A118G and alcohol sensitivity with intravenous alcohol self-administration in young adults. | Hendershot CS et al. | β | 2016 | β |
| Experimental psychopathology paradigms for alcohol use disorders: Applications for translational research. | Bujarski S et al. | β | 2016 | β |
| Kv7 channels in the nucleus accumbens are altered by chronic drinking and are targets for reducing alcohol consumption. | McGuier NS et al. | β | 2016 | β |
| Opioid Antagonists and the A118G Polymorphism in the ΞΌ-Opioid Receptor Gene: Effects of GSK1521498 and Naltrexone in Healthy Drinkers Stratified by OPRM1 Genotype. | Ziauddeen H et al. | β | 2016 | β |
| Subjective Response to Alcohol as a Research Domain Criterion. | Ray LA et al. | β | 2016 | β |
| Treatment-refractory substance use disorder: Focus on alcohol, opioids, and cocaine. | Soyka M et al. | β | 2016 | β |
| Addiction pharmacogenetics: a systematic review of the genetic variation of the dopaminergic system. | Patriquin MA et al. | β | 2015 | β |
| KCNN Genes that Encode Small-Conductance Ca2+-Activated K+ Channels Influence Alcohol and Drug Addiction. | Padula AE et al. | β | 2015 | β |
| Pharmacogenetics of alcohol use disorders and comorbid psychiatric disorders. | Helton SG et al. | β | 2015 | β |
| Pharmacotherapy for alcohol dependence: A stratified approach. | Thompson A et al. | β | 2015 | β |
| Subjective response as a consideration in the pharmacogenetics of alcoholism treatment. | Roche DJ et al. | β | 2015 | β |
| Clinical and biological moderators of response to naltrexone in alcohol dependence: a systematic review of the evidence. | Garbutt JC et al. | β | 2014 | β |
| Genetic influences on response to alcohol and response to pharmacotherapies for alcoholism. | Enoch MA | β | 2014 | β |
| Interactive effects of OPRM1 and DAT1 genetic variation on subjective responses to alcohol. | Ray LA et al. | β | 2014 | β |
| Nalmefene for the treatment of alcohol dependence: a current update. | Soyka M | β | 2014 | β |
| Pharmacogenetics of OPRM1. | Crist RC et al. | β | 2014 | β |
| Pharmacologic treatment of alcoholism. | Anton RF et al. | β | 2014 | β |
| Gene x abstinence effects on drug cue reactivity in addiction: multimodal evidence. | Moeller SJ et al. | β | 2013 | β |
| Improving clinical outcomes for naltrexone as a management of problem alcohol use. | Hulse GK | β | 2013 | β |
| Interacting effects of naltrexone and OPRM1 and DAT1 variation on the neural response to alcohol cues. | Schacht JP et al. | β | 2013 | β |
| The effects of alcohol on the pharmacokinetics and pharmacodynamics of the selective mu-opioid receptor antagonist GSK1521498 in healthy subjects. | Ziauddeen H et al. | β | 2013 | β |
| The ΞΌ-opioid receptor and treatment response to naltrexone. | Thorsell A | β | 2013 | β |
| An integrated genome-wide approach to discover tumor-specific antigens as potential immunologic and clinical targets in cancer. | Xu QW et al. | β | 2012 | β |